Real-world effectiveness of lanadelumab in hereditary angioedema: Interim results from a UK cohort study

Explore insights on hereditary angioedema (HAE) management. The poster “Real-world effectiveness of lanadelumab in hereditary angioedema: Interim results from a UK cohort study” highlights outcomes from clinical practice. These findings provide evidence on how lanadelumab performs outside of clinical trials in the UK population with having high frequency attacks (≥2 attacks per week)¹.

Lanadelumab is indicated for routine prevention of recurrent attacks of hereditary angioedema in patients aged 2 years and older².

This page is intended to be viewed on the large display.
 

References:

1. Kiani-Alikhan S, et al. RWE of lanadelumab in hereditary angioedema: Interim results from a UK cohort study, poster 21, BSI-CIPN 2025, Liverpool

2. Lanadelumab summaries of product characteristics www.medicines.org.uk/emc/product/12051/smpc Accessed November 2025